Cocrystal Pharma Inc (COCP)
1.88
+0.02
(+1.08%)
USD |
NASDAQ |
Nov 05, 11:37
Cocrystal Pharma Research and Development Expense (Annual): 15.17M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 15.17M |
| December 31, 2022 | 12.39M |
| December 31, 2021 | 8.794M |
| December 31, 2020 | 6.034M |
| December 31, 2019 | 4.004M |
| December 31, 2018 | 4.667M |
| December 31, 2017 | 5.822M |
| Date | Value |
|---|---|
| December 31, 2016 | 101.68M |
| December 31, 2015 | 47.26M |
| December 31, 2014 | 4.071M |
| December 31, 2013 | 3.862M |
| December 31, 2012 | 0.4893M |
| December 31, 2011 | 0.4232M |
| December 31, 2010 | 0.2409M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.004M
Minimum
2019
15.17M
Maximum
2023
9.279M
Average
8.794M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.31M |
| Alaunos Therapeutics Inc | 16.28M |
| Oragenics Inc | 15.49M |
| Cara Therapeutics Inc | 108.51M |
| Jaguar Health Inc | 18.60M |